成渝高速(00107.HK)預中標公路工程PPP項目 涉3.9億人幣
四川成渝高速(00107.HK)公布,全資子公司四川蜀南投資管理(蜀南公司)與四川交投建設工程股份組成聯合體,預中標蘆山縣龍門至寶盛至大川旅遊公路工程PPP項目,建設里程8.3公里,道路等級為三級公路,總投資估算約3.9億元人民幣(下同),其中政府配套投入2,000萬元。
項目採用BOT(建設-運營-移交)模式,合作期16年,其中建設期約3年,運營期約13年,項目公司將由聯合體及政府出資,其中政府出資代表方持股10%,蜀南公司持股89.99%,交投建設持股0.01%。
公司表示,項目尚處於預中標結果公示階段,若最終能確定中標、簽訂正式合同並順利實施,將有利於進一步拓展城市基礎設施業務。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.